Vaccines and Global Health: The Week in Review
29 July 2023 :: Issue 713
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
:: Think Tanks
The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond

Overview

The backsliding of immunization coverage during the COVID-19 pandemic, combined with delayed catch-up efforts has resulted in a large and growing immunity gap. There is an urgent need to close this gap, and enable millions of missed children to be vaccinated. The Essential Immunization Recovery Plan sets out a path to getting immunization back on track, framed by three key approaches – Catch-Up, Restore and Strengthen.

This document serves as the joint strategic description of this coordinated effort by WHO, UNICEF, and Gavi, the Vaccine Alliance, along with the Immunization Agenda 2030 (IA2030) Partnership, to support countries to plan and implement intensified efforts to bolster immunization programmes in 2023 and beyond.

Our strategy is driven by three core objectives:

1. CATCH-UP
   Reach children who missed vaccination during the period 2019-2022. which was partly due to the pandemic, and provide all missing vaccinations.

2. RESTORE
   Restore vaccination coverage rates for the current birth cohort in 2023 to at least 2019 levels.

3. STRENGTHEN
   Strengthen Immunization systems within PHC approaches, to improve programme resilience and accelerate towards reaching zero-dose children in line with IA2030 and Gavi 5.1 goals and targets.

WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis

New Model Essential List published today reaches a record number of medicines listed

26 July 2023  News release

Today the World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc) which include important new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions, among others. The updated Model Lists aim to facilitate greater access to innovative medicines that show clear clinical benefits. These treatments
could have a very large public health impact globally without jeopardizing the health budgets of low- and middle-income countries.

“For over 40 years, countries all over the world have relied on the WHO Essential Medicines List as a definitive, evidence-based guide to the most important medicines for delivering the biggest health impact,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Rising prices and supply chain disruptions mean that all countries now face increasing problems in ensuring consistent and equitable access to many quality-assured essential medicines. WHO is committed to supporting all countries to overcome these obstacles to increase access with equity.”

**For the 2023 update, 85 applications, encompassing over one hundred medicines and formulations, were considered** by the WHO Expert Committee on Selection and Use of Essential Medicines. The recommended changes bring the total number of medicines on the EML and EMLc to 502 and 361, respectively.

Full details of the Expert Committee’s recommendations, describing the additions, changes and removal of medicines, and decisions not to recommend medicines are available in the Executive Summary [here](#).

...**Infectious diseases**

New medicines listed for infectious diseases include:
- ceftolozane + tazobactam, a ‘reserve’ group antibiotic effective against multi-drug resistant bacteria, including difficult-to-treat infections caused by carbapenem resistant Pseudomonas aeruginosa;
- pretomanid for treatment of multidrug-resistant or rifampicin-resistant tuberculosis;
- ravidasvir (to be used in combination with sofosbuvir) for the treatment of chronic hepatitis C virus infection in adults;
- monoclonal antibodies for Ebola virus disease.

...**Section 19: Immunologicals**

Section 19.3 Vaccines

This section was reviewed by the Secretariat for consistency and full alignment with the latest WHO recommendations for routine immunization (March 2023). No changes to the current vaccine listings on the EML and EMLc were required.

::::

::::

**Pandemic Fund Allocates First Grants to Help Countries Be Better Prepared for Future Pandemics**

World Bank, July 20, 2023

The Pandemic Fund’s Governing Board has approved grants under its first round of funding allocations aimed to boost the resilience to future pandemics in 37 countries across six regions. The selected projects will receive funding to strengthen disease surveillance and early warning, laboratory systems, and health workforce.

Established in September 2022, and formally launched under Indonesia’s G20 Presidency at the G20 meetings in Bali, Indonesia last November, the Pandemic Fund is the first multilateral financing mechanism dedicated to providing multiyear grants to help low- and middle-income
countries become better prepared for future pandemics. The Fund, which is hosted by the World Bank, has already raised $2 billion in seed capital from 25 sovereign and philanthropic contributors. In May of this year, the Pandemic Fund closed its first Call for Proposals and received 179 applications from 133 countries.

The Pandemic Fund’s Governing Board met on July 19, 2023 to make its allocation decision under the first Call, based on the technical recommendations of the independent Technical Advisory Panel (TAP). Based on the proposals recommended by TAP, 19 were selected by the Board, with a focus on the three priority areas of the first Call for Proposals and will benefit 37 countries representing all World Bank geographic regions, with at least 2 projects allocated per region. About 30% of the grants allocated are for projects in sub-Saharan Africa – the region with the highest demand for Pandemic Fund grants. **Over 75% of the projects supported by the first Call are in low and lower-middle income countries.** The projects involve a variety of Implementing Entities. These projects support the Pandemic Fund’s objectives to bring additional, dedicated resources for pandemic prevention, preparedness, and response, incentivize countries to increase investments, enhance coordination among partners, and serve as a platform for advocacy...

In keeping with the Pandemic Fund’s mission to catalyze funding and promote coordination, **the $338 million of grants awarded will mobilize over $2 billion in additional resources**, adding $6 for each $1 coming from the Fund. Many of the projects involve collaboration between countries, UN agencies and Multilateral Development Banks. In responding to this call for proposals, countries have mobilized civil society and networks of delivery partners. Many of the projects involve cross-border and regional collaboration, a One Health approach—a collaborative approach that combines human, animal and ecosystem health, and consideration for gender and equity...

The Pandemic Fund’s Governing Board aims to launch the second Call for Proposals by the end of 2023, based on lessons learned from the first Call for Proposals. A listing of all grants awarded under the first call is available at the title link above.

---

**Editor’s Note**


The report’s modelling estimates that "**approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated**, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic." [see media release excerpt below]

Recognizing that public data on adult vaccinations globally is very limited [WHO: Immunization data] and the policy implications of the findings in the report overall, **we recognize that we should have provided additional information about and from the report as below.**
The IQVIA Institute for Human Data Science “contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.” The Institute is a unit of IQVIA – “a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise...With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.”

While the Global Coalition on Aging is mentioned as a collaborator and quoted in the media release, it is not mentioned in the report proper and no further information about its specific collaborative role was identified in our review.

IQVIA clarifies that its modeling and the brief overall is based in part on its proprietary database IQVIA MIDAS – “a unique platform for assessing worldwide healthcare markets. It integrates IQVIA’s national audits into a globally consistent view of the pharmaceutical market, tracking virtually every product in hundreds of therapeutic classes, and provides estimated product volumes, trends and market share through retail and non-retail channels. MIDAS data is updated monthly and retains 12 years of history.”

The research covered the following countries [panel from report]

- Algeria
- Argentina
- Australia
- Austria
- Belarus
- Belgium
- Benin
- Brazil
- Bulgaria
- Burkina Faso
- Cameroon
- Canada
- Chad
- Chile
- China
- Colombia
- Croatia
- Czech
- Ecuador
- Egypt
- Finland
- France
- Gabon
- Germany
- Greece
- Guinea
- Hong Kong
- Hungary
- India
- Indonesia
- Ireland
- Italy
- Ivory Coast
- Japan
- Jordan
- Korea
- Kuwait
- Latvia
- Lebanon
- Luxembourg
- Malaysia
- Mali
- Mexico
- Morocco
- Netherlands
- New Zealand
- Niger
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Puerto Rico
- Republic of Congo
- Romania
- Russia
- Saudi Arabia
- Senegal
- Serbia
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Switzerland
- Taiwan
- Thailand
- Togo
- Tunisia
- Turkey
- UAE
- UK
- Uruguay
- USA
- Vietnam

A key finding in the report and its footnotes [p.2]: 
"Estimated Missed Doses ~100MN (RANGE: 80-119MN) DOSES ARE ESTIMATED TO HAVE BEEN MISSED IN 2021 AND 2022”

The trends in vaccine doses for adults prior to the COVID-19 vaccination have been utilized to model the expected doses if the positive developments in vaccine uptake had continued. This modelling exercise provides two scenarios (Exhibit 2):

Scenario 1: This scenario uses the historical data trendline for the pre-pandemic period (2013-19). This period had a CAGR of 7.9% and extends the trendline up to 2022. The trendline smooths variations in the overall historical trend for the selected period (2013–19). The difference between the projected trendline for 2021 and 2022 and actual doses is 24Mn doses in 2021 and 57Mn doses in 2022, giving a total of 81Mn estimated missed doses of adult vaccines (TDaP, herpes zoster, hepatitis B, influenza and pneumococcal).

Scenario 2: This scenario uses the historical data trend line for 2013 to 2020. This period had a CAGR of 8.9% and extends the trendline to 2022. The trendline smooths variations in the overall historical trend for the selected period (2013-20). The difference between the projected trendline and actual doses is 41Mn doses in 2021 and 77Mn doses in 2022, giving a total of 119Mn estimated missed doses of adult vaccines.

The mid-point of these two scenarios gives an estimated 100Mn missed doses for the two years.

Source: IQVIA MIDAS®, June 2023; CDC (Influenza Vaccination Coverage, Children 6 months through 17 years, United States); UK Government (Vaccination coverage for children and mothers).

Notes: Adult vaccinations includes influenza; diphtheria and tetanus (Td); diphtheria, tetanus and pertussis (TDaP); hepatitis B; herpes zoster and pneumococcal. Diphtheria, tetanus and pertussis vaccinations in combination with polio or hepatitis B are not included. A 75:25% adult:pediatric split for
influenza and 1/3:2/3 split for pneumococcal has been applied in accordance with available adult and pediatric coverage (UK and US). Only hepatitis B doses of 1mL or larger were assumed for adult use.

Scenario 1 and 2 are developed from trendlines from 2013 to 2019 or 2020, respectively. Includes retail and non-retail from 76 countries covered by IQVIA MIDAS panels. These may not cover all vaccination delivery channels in each country.

::::::

**Media Release**

**New analysis shows lost ground on adult immunisation during the pandemic with 100 million doses potentially missed**

- Despite successes in Covid-19 vaccination programmes, global uptake of some other adult vaccines fell during the same timeframe—compounding already low adoption of adult immunisation
- Data also show investment in adult vaccines remains low at less than 2% of total pharmaceutical expenditure in all regions
- The analysis provides new evidence on why changes are needed, given existing data that show adult vaccine-preventable diseases are a major cause of morbidity, mortality and healthcare cost

10 July 2023

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), **estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic...**

::::::

::::::

::::::

**PHEIC**

**Polio**

**Polio this week as of 26 July 2023 - GPEI**

*Headlines*

:: “While the challenges before us are formidable and complex, I remain cautiously optimistic about the goal of interrupting transmission of poliovirus in Pakistan by the end of this year. This will require solidarity and collective action at all levels to enable rigorous implementation of the strategy, that must be fully supported by communities and the political, administrative and security leadership,” – WHO Regional Director Dr Ahmed Al-Mandhari. Read more...

:: Health teams in Sudan are going to extraordinary levels of coordination to detect polio amidst the conflict. Part of this work includes sending stool samples of children presenting with acute flaccid paralysis, a symptom of polio, across states for testing to the Argeen point of entry with Egypt. Read more...

:: nOPV2 rollout: Approximately 700 million doses of nOPV2 have been administered across 31 countries under its WHO Emergency Use Listing (EUL) to date. An additional 14 countries have met the requirements for nOPV2 use in the event of an outbreak. More information on nOPV2 is available here.
Summary of new polioviruses this week:
- Afghanistan: three WPV1 positive environmental samples
- Algeria: one cVDPV2 positive environmental sample
- Burundi: one cVDPV2 positive environmental sample
- DR Congo: one cVDPV2 case
- Nigeria: two cVDPV2 cases and three cVDPV2 positive environmental samples

Coronavirus [COVID-19]
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

WHO Weekly Epidemiological and Operational updates
Last update: 26 July 2023
Confirmed cases :: 768 560 727
Confirmed deaths :: 6 952 522
Vaccine doses administered: 13 490 832 730

Weekly epidemiological update on COVID-19 - 27 July 2023
Overview
Globally, over 868 000 new COVID-19 cases and over 3700 deaths were reported in the last 28 days (26 June to 23 July 2023). While five WHO regions have reported decreases in the number of both cases and deaths, the Western Pacific Region has reported an increase in the number of both cases and deaths. As of 23 July 2023, over 768 million confirmed cases and over 6.9 million deaths have been reported globally. Currently, reported cases do not accurately represent infection rates due to the reduction in testing and reporting globally. During this 28-day period, 52% (122 of 234) of countries and territories reported at least one case – a proportion that has been declining since mid-2022.

Our World in Data
:: 70.5% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.49 billion doses have been administered globally, and 155,445 are now administered each day.
:: 32.4% of people in low-income countries have received at least one dose.

MPOX
https://www.who.int/emergencies/situation-reports
Last Report:
Multi-country outbreak of mpox, External situation report #26 – 14 July 2023
UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Humanitarian Update, June 2023

Northern Ethiopia
Ethiopia - Situation Report, 27 Jul 2023

Somalia
Somalia: 2023 Flash and Riverine Floods Situation Report No. 3 (as of 13 July 2023)
Posted 17 Jul 2023

Türkiye/Syria Earthquakes
28 Jul 2023
Today’s top news: Syria, Niger

Ukraine
Highlights Last Updated: 26 May 2023

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

WHO & Regional Offices [to 29 Jul 2023]
https://www.who.int/news
Selected News/Announcements/Statements
28 July 2023  Departmental news

Vaccines could avert half a million deaths associated with anti-microbial resistance a year
Globally there are 4.95 million deaths per year associated with antimicrobial resistance (AMR). Low- and middle-income countries bear the burden of drug-resistant infections. AMR, which occurs when bacteria, virus, fungi and parasites change over time and no longer respond to existing treatments, was described by WHO in 2019 as one of the top ten global threats to public health – a threat to which science is playing catch-up in its efforts to mitigate.

A new study published in the BMJ Global Health has found that over half a million lives could be saved each year with the effective use of existing vaccines and the continued development of new vaccines to tackle priority pathogens. The study highlights the importance of preventive measures including vaccination in slowing and containing the spread of AMR.
The study was carried out by the World Health Organization (WHO), the International Vaccine Institute, Korea (IVI) and the London School of Hygiene & Tropical Medicine. The authors used data from 2019 to model the potential impact of 15 new and existing vaccines against pathogens in WHO’s list of bacterial priority pathogens.

They found that if the vaccines are used for key populations, not only could half a million lives be saved, but 28 million disability-adjusted life-years (DALYs) would be averted, meaning the numbers of years lost to disability or reduced lifespans as a result of infection. In the scenario where seven of the vaccines were used for broader populations, an additional 1.2 million deaths and 37 million DALYs would be prevented...

26 July 2023  News release
WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis

25 July 2023  Departmental news
Building Vaccine Manufacturing Excellence: Join The Fourth Virtual cGMP Training Marathon - Principles into Practice

25 July 2023  News release
Member States continue work on potential pandemic accord

Member States of the World Health Organization (WHO) continued their discussions towards a global accord on pandemic prevention, preparedness and response, with a view to presenting the outcome of their work to the World Health Assembly in May 2024.

The Bureau’s text of the WHO CA+ was discussed 17-21 July during the sixth meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate an international instrument to strengthen pandemic prevention, preparedness and response. This document was prepared by the Bureau of the INB following the fifth meeting of the INB based on all inputs provided by Member States, and it was distributed to all Member States and published on the WHO website in May/June 2023...

25 July 2023  Departmental news
WHO to host first global workshop on biodiversity, traditional knowledge, health and well-being

25 July 2023  Departmental news
WHO issues rapid communication on use of targeted next-generation sequencing for diagnosis of drug-resistant tuberculosis

24 July 2023  News release
WHO releases new guidance to improve testing and diagnosis of sexually transmitted infections

23 July 2023  News release
New WHO guidance on HIV viral suppression and scientific updates released at IAS 2023

WHO Regional Offices
Selected Press Releases, Announcements

**WHO African Region**
:: Uganda elevates health for all with free hepatitis testing, treatment and vaccines
28 July 2023

**WHO Region of the Americas** PAHO
:: 28 Jul 2023
**Increased use of diagnostics and medicines for viral hepatitis could save up to 100,000 lives in the Americas each year**
   The cost of treating hepatitis B and C has reduced dramatically the last 10 years, making hepatitis medicines an affordable way to control the disease and prevent deaths Washington, D.C., 27 July 2023 (PAHO) – On the eve of World Hepatitis Day, the Pan American Health Organization (PAHO) is urging countries to rapidly scale-up access to...
:: 26 Jul 2023
**Questions and answers on avian influenza A(H5N1)**
 "The avian influenza epidemic poses a real threat to animals and a potential threat to humans." July 2023 (PAHO/WHO)—In January this year, the Pan American Health Organization (PAHO) warned about outbreaks of highly pathogenic avian influenza in birds in countries of the Americas. For the first time, a human case of avian influenza A (H5N1) was...
:: 25 Jul 2023
**PAHO and Inter-American Development Bank celebrate 5-year collaboration on digital health in the Americas**
   Washington D.C. 25 July 2023 – At an event to celebrate five years of collaboration in information systems and digital health between the Pan American Health Organization (PAHO) and the Inter-American Development Bank (IBD), the PAHO Director, Dr. Jarbas Barbosa, underscored the crucial role of digital transformation in pandemic recovery and...

**WHO South-East Asia Region** SEARO
:: Bhutan, Timor-Leste eliminate rubella; Achieve 2023 target of measles and rubella elimination
21 July 2023 News release New Delhi
   The World Health Organization South-East Asia Region today announced Bhutan and Timor-Leste have eliminated rubella, a highly contagious disease that causes serious illness and irreversible birth defects in newborns of women infected during pregnancy, but preventable through vaccination. Bhutan and Timor-Leste had eliminated measles in 2017 and 2018 respectively, and now join Maldives and Sri Lanka to achieve elimination of measles and rubella by 2023, a flagship priority program of WHO South-East Asia Region...

**WHO European Region** EURO
*No new digest content identified.*

**WHO Western Pacific Region**
*No new digest content identified.*

::::::

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

28 July 2023 | Circulating vaccine-derived poliovirus type 2 (cVDPV2) - United Republic of Tanzania

28 July 2023 | Circulating vaccine-derived poliovirus type 2 (cVDPV2) - Kenya

25 July 2023 | Guillain-Barré Syndrome - Peru

24 July 2023 | Middle East Respiratory Syndrome - United Arab Emirates

::: New WHO Publications

https://www.who.int/publications/i

Selected

26 July 2023
The Big Catch-Up: An Essential Immunization Recovery Plan for 2023 and Beyond

26 July 2023
AWaRe classification of antibiotics for evaluation and monitoring of use, 2023

26 July 2023
WHO Model List of Essential Medicines for Children - 9th list, 2023

26 July 2023
WHO Model List of Essential Medicines - 23rd list, 2023

26 July 2023
The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert...

25 July 2023
Entomological manual for onchocerciasis elimination programmes

24 July 2023
Community experiences of the 2022–2023 mpox outbreak in Europe and the Americas

24 July 2023
Target product profile for a diagnostic test to confirm leprosy in individuals with clinical signs and...

23 July 2023
Use of targeted next-generation sequencing to detect drug-resistant tuberculosis
The role of HIV viral suppression in improving individual health and reducing transmission

USA – HHS, FDA, CDC

HHS
News
No new digest content identified.

FDA
Press Announcements
FDA Roundup: July 28, 2023
... On Thursday, the FDA approved Ervebo, a vaccine for the prevention of Ebola virus disease caused by Zaire ebolavirus in individuals 12 months through 17 years of age. Ervebo has been approved for use in individuals 18 years of age and older since December 2019. Cases of Ebola are very rare in the U.S., and those that have occurred have been the result of infections acquired by individuals in other countries who then traveled to

FDA VRBPAC
Advisory Committee Calendar
No new meetings identified.

CDC/ACIP [U.S.] [to 29 Jul 2023]
http://www.cdc.gov/media/index.html
Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
August 3, 2023  11:00am – 3:30pm EDT
Agenda  Webcast Link
ACIP meetings are virtual. No registration is required to watch the webcasts.

MMWR Weekly
https://www.cdc.gov/mmwr/index2023.html
July 28, 2023 / No.30
PDF of this issue
- Travel-Associated Dengue Cases — United States, 2010–2021
- Demographic Disparities in Mpox Vaccination Series Completion, by Route of Vaccine Administration — California, August 9, 2022–March 31, 2023
- Notes from the Field: Cruise Ship Norovirus Outbreak Associated with Person-to-Person Transmission — United States Jurisdiction, January 2023
QuickStats: Percentage of Adults Aged ≥18 Years who Received an Influenza Vaccination in the Past 12 Months, by Race and Ethnicity and Family Income — National Health Interview Survey, United States, 2021

Europe

European Medicines Agency [EMA]
News & Press Releases
News: Paving the way towards coordinated clinical trials in public health emergencies in the EU (new)
Last updated: 25/07/2023

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
World Hepatitis Day 2023: need to scale up efforts to address hepatitis B and C
Campaign - 28 Jul 2023

Weekly COVID-19 country overview
Epidemiological update - 27 Jul 2023

Africa CDC [to 29 Jul 2023]
http://www.africacdc.org/
News
Statement
The Africa Centres for Disease Control and Prevention (Africa CDC) Statement on the Allocation of Funding in the First Call for Proposals by the Pandemic Fund
27 July 2023

... Africa CDC commends the Pandemic Fund for the outcome of the first call for proposals with 19 Grants approved, which is praiseworthy given the gaps in meeting the initial commitment of 1.6 billion dollars pledged by donors at the Fund’s launching. Africa CDC notes that only 9% of African countries (5 out of the 55 AU Member States) representing less than 5% of Africa’s population will benefit from this first call of proposals. While congratulating the five countries and committing to support them for implementation, Africa CDC remains concerned about the limited impact of this first allocation on pandemic preparedness, prevention, and response (PPPR) in Africa due to its limited size and lack of regional approach.

Africa CDC notes that Africa is the only region without a regional proposal. In contrast, other regions adopted a regional approach to maximize the impact of the Pandemic Fund on their entire countries
and populations: Caribbean region with 12 countries, South America with 7 countries, and Central Asia with 5 countries. The considerable discrepancy stems from the Pandemic Fund’s failure to acknowledge the vital role that Africa CDC could have played as an Implementing Entity for the Fund, considering its central role in supporting health initiatives across the continent.

Overlooking the inclusion of Africa CDC, which is the sole continental public health institution, was an unfortunate oversight. As a result, Africa’s health security gaps remain inadequately addressed, leading to the absence of multi-country/regional proposals from the continent...

::::
:::

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 29 Jul 2023]
http://en.nhc.gov.cn/
News
*No new digest content identified.*

**National Medical Products Administration — PRC** [to 29 Jul 2023]
http://english.nmpa.gov.cn/
News
*China issues plan for mpox disease prevention, control* 2023-07-28

Chinese health authorities have issued a plan for the prevention and control of mpox disease, the national administration of disease prevention and control announced on Thursday.

**China CDC Weekly Reports: Current Volume (5)**
2023-07-28 / No. 30
View PDF of this issue

- Notes from the Field: No Novel Prevalent Mutations Detected in the Circulating Strains of BF.7, BA.5.2, DY, and XBB — China, November 2022 to June 2023
- Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, January 2023*
- Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, February 2023*
- Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, March 2023*
Organization Announcements

Paul G. Allen Frontiers Group  [to 29 Jul 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 29 Jul 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 29 Jul 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X  [to 29 Jul 2023]
https://carb-x.org/
News
07.27.2023  |  GERMAN GOVERNMENT RENEWS COMMITMENT TO CARB-X
Millions injected into antimicrobial resistance research and development

Center for Vaccine Ethics and Policy – GE2P Global Foundation  [to 29 Jul 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Publications-Digests/Statements
:: Vaccines and Global Health: The Week in Review - Current edition
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – July 2023
:: Public Consultations Watch :: Global Calls for Input/Public Comment - 19 July 2023 – Issue 05
CEPI – Coalition for Epidemic Preparedness Innovations [to 29 Jul 2023]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 29 Jul 2023]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 Jul 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 29 Jul 2023]
https://dukeghic.org/
Report
No new digest content identified.

EDCTP [to 29 Jul 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 29 Jul 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 29 Jul 2023]
http://www.euvaccine.eu/
Latest News, Events
EVI
TRANSAVC2 concludes: key achievements and new horizons
July 2023 The TRA
Over the duration of the TRANSVAC2 project, spanning from April 1, 2017, to April 30, 2023, the primary focus was the establishment of an efficient and well-coordinated research and innovation environment dedicated to providing scientific and technical services to the vaccine research and development (R&D) community...

Evidence Aid  [to 29 Jul 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/

Impact of disasters caused by natural hazards on non-communicable diseases
Added July 20, 2023

Nurse education and training for disasters
Added July 19, 2023

The seismic risks of open spaces in the built environment
Added July 18, 2023

Fondation Merieux  [to 29 Jul 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 29 Jul 2023]
https://www.gavi.org/
News Releases
28 July 2023
New funding boosts efforts to vaccinate “zero-dose” children in the Democratic Republic of the Congo
:: DRC will receive US$ 59.7 million through Gavi’s Equity Accelerator Fund to help reduce the number of zero-dose children – who receive no basic vaccines – by 35% by 2025
:: The funding, which builds on the Mashako Plan 2.0 and the Kinshasa Declaration, will support activities including tracking vaccinations using GPS and SMS, identifying zero-dose children with community healthcare workers, door-to-door outreach, and tackling gender-related obstacles that impact demand across new priority areas

GHIT Fund   [to 29 Jul 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified.

Global Fund   [to 29 Jul 2023]
*News & Stories*
*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 29 Jul 2023]
https://www.glopid-r.org/news/
*News*
*No new digest content identified.*

**Hilleman Laboratories** [to 29 Jul 2023]
http://www.hilleman-labs.org/
*News & Insights*
*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 29 Jul 2023]
https://www.hhmi.org/news
*Press Room*
*Science Education* Jul 27 2023
**HHMI Awards 50 New Gilliam Fellowships to Advance Equity and Inclusion in Science**
Fifty graduate students and their advisers join the thriving community supported by the HHMI Gilliam Fellows Program.

**Human Vaccines Project** [to 29 Jul 2023]
http://www.humanvaccinesproject.org/
*News*
*No new digest content identified.*

**IAVI** [to 29 Jul 2023]
https://www.iavi.org/
*Latest News*
*No new digest content identified.*

**INSERM** [to 29 Jul 2023]
https://www.inserm.fr/en/home/
*Press Releases*
*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
*No new digest content identified.*
Public Consultation: ICH E6(R3) Principles, Annex 1 and Annex 2

The E6(R3) EWG is working on the revision of the E6(R2) Guideline “Good Clinical Practice” (GCP) with a view to addressing the application of GCP principles to the increasingly diverse trial types and data sources being employed to support regulatory and healthcare related decision-making on drugs, and provide flexibility whenever appropriate to facilitate the use of technological innovations in clinical trials. Additional information may also be found in ICH Reflection Paper on “GCP Renovation” on the ICH Reflection Paper page. When complete, E6(R3) will be composed of an overarching principles and objectives document, Annex 1 and Annex 2.

E6(R3) Draft Guideline

Public consultation dates:
FDCA, USA – Comment period ends 05 September 2023
ANVISA, Brazil - Deadline for comments by 31 August 2023
EC, Europe - Deadline for comments by 26 September 2023
MHRA, UK - Deadline for comments by 31 August 2023
TFDA, Chinese Taipei - Deadline for comments by 31 August 2023

ICRC [to 29 Jul 2023]
What’s New  [Selected]
Bangladesh: Over 227,000 patients received life-saving medical assistance thanks to the Kuwait Red Crescent Society’s support

Thanks to this agreement, the ICRC, along with its Bangladesh Red Crescent Society partners, contributed to the growth of the Emergency Department, while increasing the skillset of its medical professionals.
24-07-2023  |  News release

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 29 Jul 2023]
Press Releases [Selected]
No new digest content identified.

Institut Pasteur  [to 29 Jul 2023]
Press Documents
No new digest content identified.

ISC / International Science Council [to 29 Jul 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Blogs
Global science needs a new approach to tackle climate change and complex sustainability question
27.07.2023

Blogs
The ISC addresses the UN High Level Political Forum and meets with the UN Secretary General
24.07.2023

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC [to 29 Jul 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
As Immunization Coverage Begins to Recover, Inequities Remain
July 2023
Although we are beginning to recover from the immunization backslide caused by the COVID-19 pandemic, the recently released WHO and UNICEF national estimates of immunization coverage (WUENIC) shows that continued efforts are needed to ensure equitable access to vaccines. These life-saving vaccines are critical to prevent unnecessary illnesses and deaths and to provide a higher [...]

IVI [to 29 Jul 2023]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 29 Jul 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
Johns Hopkins Center for Health Security co-hosts India–United States Strategic Dialogue to discuss critical biosecurity issues
July 26, 2023

MSF/Médecins Sans Frontières. [to 29 Jul 2023]
http://www.msf.org/
Latest [Selected Announcements]
Conflict in Sudan
Hundreds of thousands face disease in overcrowded camps in White Nile state
Project Update 27 Jul 2023

National Academy of Medicine - USA [to 29 Jul 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 29 Jul 2023]
https://www.nationalacademies.org/newsroom?
News
U.S. Should Create a Federal Entity Responsible for Advancing Racial, Ethnic, and Tribal Health Equity, and Implement a Health Equity Policy Audit and Score Card
The U.S. should create a federal entity responsible for advancing racial, ethnic, and tribal health equity, implement an equity audit of current agency policies, and design a score card to assess how proposed legislation might impact health equity.
Date: 2023-07-27
Type: News Release

National Vaccine Program Office - U.S. HHS [to 29 Jul 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
September 21-22, 2023 NVAC Meeting

NIH [to 29 Jul 2023]
http://www.nih.gov/
News Releases
No new digest content identified.

PATH [to 29 Jul 2023]
https://www.path.org/media-center/
Press Releases
PATH releases Diversity, Equity, and Inclusion 2025 Strategy
Published: July 2023 Announcement
**Rockefeller Foundation** [to 29 Jul 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
No new digest content identified.

**Sabin Vaccine Institute** [to 29 Jul 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

**UNAIDS** [to 29 Jul 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

**UNICEF** [to 29 Jul 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
Press release 27 July 2023
1 in 2 children in Europe and Central Asia are exposed to high heatwave frequency, double the global average

GENEVA, 27 July 2023 – Around half of children in Europe and Central Asia – or 92 million – are exposed to high heatwave frequency, according to an analysis of the latest available data from 50 countries published today by UNICEF in a new policy brief. This is double the global average of 1 in 4 children exposed to high heatwave frequency. Beat...

Press release 24 July 2023
Severe violations of children’s rights an ‘hourly occurrence’ in Sudan, warns UNICEF

PORT SUDAN/NEW YORK, 24 July 2023 – As the brutal conflict in Sudan hits 100 days, UNICEF has received reports of a staggering 2,500 severe violations of children’s rights —an average of at least one an hour. As these are just the numbers reported to UNICEF sources, the true figure is likely to be far higher, and a grim reminder of the day-to-day...

Press release 23 July 2023
UNICEF: Against the odds, children begin the new school year in Rohingya refugee camps

COX’S BAZAR, Bangladesh, 23 July 2023 – Against the odds of displacement, fires burning down learning centres, and Cyclone Mocha’s wrath, classrooms in the Rohingya refugee camps in Bangladesh
are filling up today with children, excited on the first day of school. Thanks to expanded education opportunities for teenagers and girls,

**Unitaid** [to 29 Jul 2023]
https://unitaid.org/
Featured News
27 July 2023
*World Hepatitis Day: Unitaid is pioneering urgent solutions to tackle hepatitis C*

**Vaccine Equity Cooperative [nee Initiative]** [to 29 Jul 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 29 Jul 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

**Vaccine Confidence Project** [to 29 Jul 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 29 Jul 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
News
*Vaccine Update for Providers*
July 2023

**Wellcome Trust** [to 29 Jul 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute** [to 29 Jul 2023]
Press Releases
Press Release  Jul. 26, 2023
*Wistar-Led Team Awarded More Than $12 Million Grant from the NCI to Investigate Link Between Epstein-Barr Virus and Carcinomas*
PHILADELPHIA — (JULY 26, 2023) — It’s been known since the 1960s that Epstein-Barr Virus (EBV) causes a variety of cancers, but research has overwhelmingly focused on its connection to lymphomas.

**WFPHA: World Federation of Public Health Associations** [to 29 Jul 2023]
https://www.wfpha.org/
*Latest News - Blog*
**The Alliance of Public Health Associations of the Americas: New Board Members**
Jul 25, 2023
The Alliance of Public Health Associations of the Americas: New Board Members WFPHA congratulates the new elected board members of the Alliance of the Public Health Associations of the Americas (AASPA), Anulfo Lopez as President, Rosana Onocko as...

**World Medical Association [WMA]** [to 29 Jul 2023]
*Press Releases*
No new digest content identified.

**World Organisation for Animal Health** [to 29 Jul 2023]
https://www.oie.int/en/
*Press Releases, Statements*
Selected Press Releases
No new digest content identified.

::::::

**ARM [Alliance for Regenerative Medicine]** [to 29 Jul 2023]
Selected Press Releases
No new digest content identified.

**BIO** [to 29 Jul 2023]
*Press Releases*
No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 29 Jul 2023]
http://www.dcvmn.org/
*News; Upcoming events*
**24th DCVMN Annual General Meeting 2023**
September 19 - 21, 2023
Cape Town, South Africa
Fourth meeting of the Working Group on Amendments to the International Health Regulations


... With pragmatism as the cornerstone, we need to focus on preserving what works well – such as the innovation ecosystem – and removing barriers that are impacting our collective abilities to respond to public health risks. Looking to the future, early access to pathogens, open borders without upstream or downstream trade restrictions, and a strong IP incentive framework are what is needed.

In line with its technical scope, we encourage the WGIHR to consider:

- Ensuring and promoting the sharing of outbreak information, including the immediate and unhindered access to pathogens, as a critical step to help inform a coordinated global response to outbreaks and trigger R&D
- Delineating equitable access discussions under the WHO CA+

Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on Amendments to the International Health Regulations: Agenda item 3

On 24 July, IFPMA delivered a statement for agenda item 3 at the "Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response and the Working Group on Amendments to the International Health Regulations (WGIHR) (2005)" in Geneva.

... On the joint issue discussed at IHR and INB related to access to pathogens and equitable access to pandemic countermeasures, we are concerned to see the Pandemic Influenza Preparedness (PIP) model used as a reference for developing solutions as we consider it unfit to ensure better pandemic preparedness and response, and not practically replicable beyond influenza for the following reasons:

1. There is a well-established, centralized tracking and sharing of influenza pathogens. For all other pathogens, sharing occurs through various networks, as well as bilaterally. Bringing all under the umbrella of WHO would be technically and legally challenging and would undermine the efforts of already established networks.
2. There are only a handful of influenza manufacturers, making it possible to sign Standard Material Transfer Agreements (SMTA2s) in inter-pandemic periods. Identifying who will be the successful innovators in the next pandemic is not possible. Applying the PIP model would imply signing SMTA2s with hundreds, possibly thousands of entities involved in vaccine, therapeutic, and diagnostic R&D related to pathogens of pandemic potential. You have to bear in mind that, over the last decade, only 14 SMTA2s were successfully signed.
3. The PIP model does not provide an obligation to share pathogens and does not solve the issue of burdensome national access- and benefit-sharing laws being applied to influenza samples, where
we have already seen cases of national ABS rules negatively impacting supplies of seasonal influenza vaccines.

4. An SMTA does not address export restrictions, which were a key barrier to equitable access during COVID-19, and hence might prevent companies’ ability to comply with supply obligations.

5. Finally, PIP has fortunately never been used and tested since its creation and remains a theoretical model.

International Alliance of Patients’ Organizations – IAPO [to 29 Jul 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems (July 2023)
On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to pharmaceutical quality amongst national regulatory authorities worldwide.

PhRMA [to 29 Jul 2023]
http://www.phrma.org/
Press Releases
No new digest announcements identified

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D
28 July 2023

Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
28 July 2023
- Agreement furthers Alexion’s ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca
- Portfolio includes preclinical gene therapy programmes and enabling technologies with potential across several therapeutic areas
GSK

Press releases for media
24 July 2023

ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency

Cabotegravir is the first and only long-acting injectable option for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1
Press Releases  
 Jul 28, 2023  United States  
 Janssen Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy EDURANT®

Merck  
News releases  
July 27, 2023  
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 26, 2023  
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk(Stage IIB-IV) Melanoma

Moderna  
Press Releases  
26 July, 2023  
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

Nanogen  
News - No new digest announcements identified

Novartis  
News - No new digest announcements identified

Novavax  
Press Releases - No new digest announcements identified

Pfizer  
Recent Press Releases  
07.27.2023  
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy  
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.  
Effective today, Chris Boshoff, M.D., PhD, will join Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla...

R-Pharm  
https://rpharm-us.com/index.php  
[No news or media page identified]
Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
2023/07/28 | Press Releases
SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia’s Vaccine Supply

SK Biosciences
Press Releases - No new digest announcements identified

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] [No website identified]
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023 Issue 2
https://www.tandfonline.com/toc/uabr21/current
Article
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 7: E467-572
https://journalofethics.ama-assn.org/issue/how-we-over-rely-bmi
How We Over Rely on BMI
Patients who are fat or perceived as fat are commonly characterized by some clinicians as unreliable narrators of their own health histories. Negative bias can undermine diagnoses, intervention decisions, and even what some clinicians think fat patients deserve. Fat is widely considered a clinical threat, and obesity is a descriptor applied to patients with BMIs at or over 30. While weight and BMI can be helpful clinical indicators, many of its applications are overvalued, imprecise, contested, and can incur substantial iatrogenic harm. This theme issue examines clinical and ethical shortcomings of medicine’s current approaches to fat.

American Journal of Infection Control
July 2023 Volume 51 Issue 7 p725-846
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
July 2023 Volume 65 Issue 1 p1-172
[Reviewed earlier]

American Journal of Public Health
August 2023 113(8)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Annals of Internal Medicine
July 2023  Volume 176, Issue 7
https://www.acpjournals.org/toc/aim/current

Original Research
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue
A GeoSentinel Analysis
Ralph Huits, MD, PhD, Kristina M. Angelo, DO, Bhawana Amatya, MD, Sapha Barkati, MD, MSc, … et al.
Pages:940–948

Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV
Monica Gandhi, MD, MPH, Matthew Hickey, MD, Elizabeth Imbert, MD, Janet Grochowski, PharmD, … et al.
Pages:969–974

Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection - A Prospective Cohort Study
Apurv Soni, MD, PhD, Carly Herbert, BA, Honghuang Lin, PhD, Yi Yan, PhD, Caitlin Pretz, MS, … et al.
Pages:975–982

Special Articles
COVID-19 Is No Longer a Public Health Emergency: Implications for Patients and Clinicians
FREE
Christine Laine, MD, MPH and Darilyn V. Moyer, MD
Pages:983–984

Artificial Intelligence – An International Journal
Volume 320  July 2023
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 29 Jul 2023)
[No new digest content identified]

BMJ Global Health
July 2023 - Volume 8 - 7
https://gh.bmj.com/content/8/7
Prevalence of tuberculosis and associated factors among presumptive TB refugees residing in refugee camps in Ethiopia

Tuberculosis (TB) causes significant morbidity and mortality in refugee populations. Although Ethiopia is the third largest refugee-hosting country in Africa, there is limited published data on the prevalence of TB in this context. The study aimed to determine the prevalence of TB and associated factors among presumptive TB refugees residing in refugee camps in Ethiopia.

Authors: Abyot Meaza, Bazezew Yenew, Miskir Amare, Ayinalem Alemu, Michael Hailu, Dinka Fikadu Gamtesa, Mirgissa Kaba, Girmay Medhin, Gobena Ameni and Balako Gumi

Citation: BMC Infectious Diseases 2023 23:498
Content type: Research Published on: 28 July 2023

Communication of patients’ and family members’ ethical concerns to their healthcare providers

Little is known about communication between patients, families, and healthcare providers regarding ethical concerns that patients and families experience in the course of illness and medical care. To address this gap, the study aimed to investigate the communication of patients’ and family members’ ethical concerns to their healthcare providers.

Authors: Mariam Noorulhuda, Christine Grady, Paul Wakim, Talia Bernhard, Hae Lin Cho and Marion Danis

Citation: BMC Medical Ethics 2023 24:56
Content type: Research Published on: 29 July 2023

Estimating the full health and economic benefits of current and future influenza vaccines

In the dynamic landscape of respiratory virus vaccines, it is crucial to assess the value of novel mRNA and combination influenza/COVID-19 vaccines in low- and middle-income countries. Modeling studies, such as the one conducted by Waterlow et al., provide vital information about the cost–benefit trade-offs associated with these vaccines.
potential of these products compared to currently licensed vaccines. However, this approach only accounts for directly measured medically attended influenza-associated illnesses and has two major limitations. First, this method fails to capture the full disease burden of influenza (including non-respiratory and non-medically attended influenza illnesses), which are particularly important drivers of disease burden in infants and older adults. Second, the model does not describe the ancillary benefits of influenza vaccination such as the attenuation of severe disease, prevention of severe non-respiratory outcomes (e.g., myocardial infarctions), or reduced antibiotic use. To obtain a comprehensive understanding of the benefits of influenza vaccines, we must strive to improve the inputs for future modeling-based evaluations.

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 29 Jul 2023)
COVID-19 vaccine registry for pregnant women: policy to control complications of vaccination in pregnant women in 2021–2022
Data management related to COVID-19 vaccination in pregnant women is vital to improve the treatment process and to establish preventive programs. Implementing a registry to manage data is an essential part of ...
Authors: Farkhondeh Asadi, Roya Shakiba, Reza Rabiei, Hassan Emami and Azam Sabahi
Citation: BMC Pregnancy and Childbirth 2023 23:542
Content type: Research Published on: 27 July 2023

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 29 Jul 2023)
Migration and health research: past, present, and future
Global migration continues to rise at unprecedented rates. Migrants are an extremely heterogeneous group and face diverse health needs related to infectious diseases, sexual and reproductive health, non-commun...
Authors: Shira M Goldenberg and Florian Fischer
Citation: BMC Public Health 2023 23:1425
Content type: Editorial Published on: 25 July 2023

BMC Research Notes
http://www.biomedcentral.com/bmcresearchnotes/content
(Accessed 29 Jul 2023)
[No new digest content identified]

BMJ Evidence-Based Medicine
August 2023 - Volume 28 - 4
https://ebm.bmj.com/content/28/4
[New issue; No digest content identified]
BMJ Open
May 2023 - Volume 13 - 5
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the Atomic Scientists
July 2023
https://thebulletin.org/magazine/2023-07/
Special Issue: Oppenheimer
Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(7); 2023 Jul 1
[Reviewed earlier]

Cell
Jul 06, 2023 Volume 186 Issue 14 p2951-3136
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 49, Issue 4 Pages: 617-785 July 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 114, Issue 1 Pages: 1-238 July 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

Clinical Therapeutics
June 2023 Volume 45 Issue 6 p483-616
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 20 Issue 4, August 2023
https://journals.sagepub.com/toc/ctja/20/4
Articles
[Reviewed earlier]
Conflict and Health
http://www.conflictandhealth.com/
[Accessed 29 Jul 2023]
[No new digest content identified]

Contemporary Clinical Trials
Volume 130  July 2023
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/130/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 6, Issue 3 / June 2023
https://www.liebertpub.com/toc/crispr/6/3
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Medical Research and Opinion
Volume 39, Issue 7  2023
https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
August 2023 - Volume 36 - Issue 4
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
INFECTIONS OF THE IMMUNOCOMPROMISED HOST
Machine learning and artificial intelligence for the diagnosis of infectious diseases in immunocompromised patients
Tran, Nam K; Kretsch, Cileah; LaValley, Clayton; More

NOSOCOMIAL AND HEALTHCARE RELATED INFECTIONS
Burden of influenza in the elderly: a narrative review
Conrad, Anne; Valour, Florent; Vanhems, Philippe

Current Protocols in Human Genetics
Developing World Bioethics
Volume 23, Issue 2  Pages: 89-195  June 2023
https://onlinelibrary.wiley.com/toc/14718847/current
**Special Issue: Reproductive Justice: Inequalities in the Global South**
[Reviewed earlier]

Development in Practice
Volume 33, Issue 5, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 4  July 2023
https://onlinelibrary.wiley.com/toc/14677679/current
**Articles**
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 3  Pages: 543-846  July 2023
**Papers**

_Governance and the design of post-disaster policies: a comparative analysis from Latin America and the Caribbean_
Marco Córdova, Jonathan Menoscal, Esteban Moreno Flores
Pages: 766-787
First Published: 02 September 2022

_Gaps in humanitarian WASH response: perspectives from people affected by crises, practitioners, global responders, and the literature_
Travis Yates, Andy Bastable, John Allen, Cecilie Hestbæk, Bushra Hasan, Paul Hutchings, Monica Ramos, Tula Ngasala, Daniele Lantagne
Pages: 830-846
First Published: 22 November 2022
EMBO Reports
Volume 24  Issue 7  5 July 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 6—June 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 43  June 2023
https://www.sciencedirect.com/journal/epidemics/vol/43/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 4  Pages: 1-39  July–August 2023
https://onlinelibrary.wiley.com/toc/25782363/current
Trust and HIV-transmission trials :: Translational science and public input
[Reviewed earlier]

Ethics & International Affairs
Volume 37 - Issue 1 - Spring 2023
https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 28  June 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 3, June 2023
https://academic.oup.com/eurpub/issue/33/3
[Reviewed earlier]

**Expert Review of Vaccines**
Vol 22 (1) 2023  *Issue In Progress*
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

**Foreign Affairs**
May/June 2023  Volume 102, Number 3
https://www.foreignaffairs.com/issues/2023/102/3
[Reviewed earlier]

**Forum for Development Studies**
Volume 50, 2023 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

**Genetics in Medicines**
Volume 25, Issue 7  July 2023
https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/7
[Reviewed earlier]

**Genome Medicine**
https://genomemedicine.biomedcentral.com/articles
[Accessed 29 Jul 2023]
[No new digest content identified]

**Global Health Action**
Volume 16, Issue 1 (2023)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**
Vol. 11, No. 3  June 21, 2023
http://www.ghspjournal.org/content/current
[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 29 Jul 2023]
Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 29 Jul 2023]
[No new digest content identified]

Health and Human Rights
Volume 25, Issue 1, June 2023,
https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/
Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks
...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

Health Economics, Policy and Law
Volume 18 - Issue 3 - July 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 5, June 2023
https://academic.oup.com/heapol/issue/38/5
[Reviewed earlier]

Health Research Policy and Systems
Human Gene Therapy
Volume 34, Issue 13-14 / July 2023
https://www.liebertpub.com/toc/hum/34/14-12
[New issue; No digest content identified]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Jul 11, 2023  Volume 56  Issue 7  p1429-1698
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 29 Jul 2023]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 29 Jul 2023]
[No new digest content identified]

International Health
Volume 15, Issue 4, July 2023
https://academic.oup.com/inthealth/issue/15/4
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 10 No. 7 (2023): July 2023
https://www.ijcmph.com/index.php/ijcmph/issue/view/102
[Reviewed earlier]

International Journal of Epidemiology
Volume 52, Issue 3, June 2023
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 16 Issue 3 2023
https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3
Table of contents
[Reviewed earlier]

JAMA
July 25, 2023, Vol 330, No. 4, Pages 295-386
https://jamanetwork.com/journals/jama/currentissue
Editorial
Translating Clinical Trial Results to Clinical Practice During a Pandemic
Andre C. Kalil, MD, MPH; Angela Huttner, MD; Carlos A. Gomez, MD

JAMA Health Forum
July 2023, Vol 4, No. 7
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

JAMA Pediatrics
July 2023, Vol 177, No. 7, Pages 655-742
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
July 2023 - Volume 21 - Issue 7
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
Journal of Adolescent Health
July 2023  Volume 73  Issue 1  p1-212
https://www.jahonline.org/current

Journal of Artificial Intelligence Research
Vol. 77 (2023)
https://www.jair.org/index.php/jair
Contents

Journal of Community Health
Volume 48, issue 4, August 2023
https://link.springer.com/journal/10900/volumes-and-issues/48-4
Integrating HPV Vaccination Within PrEP care Delivery for Underserved Populations: A Mixed Methods Feasibility Study
Authors (first, second and last of 5)
Christopher W. Wheldon
Kevin J. Sykes
Bradley N. Collins
Content type: Original Paper
Published: 10 March 2023
Pages: 640 - 651

Parent-reported Barriers and Parental Beliefs Associated with Intentions to Obtain HPV Vaccination for Children in a Primary care Patient Population in Minnesota, USA
Authors (first, second and last of 6)
Xuan Zhu
Robert M. Jacobson
Lila J. Finney Rutten
Content type: Original Paper
Published: 15 March 2023
Pages: 678 – 686

Journal of Current Medical Research and Opinion
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
June 18, 2023  Vol 6, No 06 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/68
[Reviewed earlier]
Journal of Development Economics
Volume 164  September 2023
[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 3, July 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2023 - Volume 77 - 6
https://jech.bmj.com/content/77/4
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 16, Issue 2  Pages: 101-258  June 2023
https://onlinelibrary.wiley.com/toc/17565391/current
ARTICLES
[Reviewed earlier]

Journal of Global Ethics
Volume 19, Issue 1 (2023)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 3, August 2023
https://muse.jhu.edu/issue/50808
Table of Contents
[New issue; No digest content identified]

Journal of Immigrant and Minority Health
Volume 25, issue 3, June 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023  Issue 2

Articles
[Reviewed earlier]

Journal of the Royal Society – Interface
July 2023  Volume 20  Issue 204
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 30, Issue 4, May 2023
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 97 • Number 7 • July 2023
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Jul 29, 2023  Volume 402  Number 10399  p347-424
https://www.thelancet.com/journals/lancet/issue/current
Editorial
A broader vision for women’s health
The Lancet

The Lancet Child & Adolescent Health
Aug 2023  Volume 7  Number 8  p519-598
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Jul 2023  Volume 5  Number 7  e395-e476
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Aug 2023  Volume 11  Number 8  e1137-e1313
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]
Lancet Infectious Diseases
Jul 2023 Volume 23 Number 7 p763-878, e227-e265
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Jul 2023 Volume 8 Number 7 e473-e574
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Jul 2023 Volume 11 Number 7 p577-662, e61-e72
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 27, issue 8, August 2023
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 43 Issue 5, July 2023
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 2 Pages: 249-635 June 2023
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Molecular Therapy
Jul 05, 2023 Volume 31 Issue 7 p1859-2298
https://www.cell.com/molecular-therapy/current
[Reviewed earlier]

Nature
Volume 619 Issue 7971, 27 July 2023
https://www.nature.com/nature/volumes/619/issues/7971
Editorial 25 Jul 2023
ChatGPT is a black box: how AI research can break it open

Despite their wide use, large language models are still mysterious. Revealing their true nature is urgent and important.

Nature Biotechnology
Volume 41 Issue 7, July 2023
https://www.nature.com/nbt/volumes/41/issues/7
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 29 Jul 2023)
[No new digest content identified]

Nature Genetics
Volume 55 Issue 7, July 2023
https://www.nature.com/ng/volumes/55/issues/7
[Reviewed earlier]

Nature Human Behaviour
Volume 7 Issue 6, June 2023
https://www.nature.com/nathumbehav/volumes/7/issues/6
[Reviewed earlier]

Nature Medicine
Volume 29 Issue 7, July 2023
https://www.nature.com/nm/volumes/29/issues/7
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 22 Issue 7, July 2023
https://www.nature.com/nrd/volumes/22/issues/7
[Reviewed earlier]

Nature Reviews Genetics
Volume 24 Issue 7, July 2023
https://www.nature.com/nrg/volumes/24/issues/7
[Reviewed earlier]

Nature Reviews Immunology
New England Journal of Medicine
July 27, 2023  Vol. 389 No. 4
https://www.nejm.org/toc/nejm/medical-journal
Review Article
**AI in Medicine: Artificial Intelligence in U.S. Health Care Delivery**
N.R. Sahni and B. Carrus

nPj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 29 Jul 2023]
[No new digest content identified]

Pediatrics
Volume 152, Issue 1 July 2023
https://publications.aap.org/pediatrics/issue/152/1
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 7, July 2023
https://link.springer.com/journal/40273/volumes-and-issues/41-7
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 29 Jul 2023)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 29 Jul 2023)
[No new digest content identified]

PLOS Global Public Health
https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 29 Jul 2023)
[No new digest content identified]
Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study
Xi Xiong, David Tak Wai Lui, Matthew Shing Hin Chung, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Eric Yuk Fai Wan, Celine Sze Ling Chui, Xue Li, Franco Wing Tak Cheng, Ching-Lung Cheung, Esther Wai Yin Chan, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong, Ian Chi Kei Wong
Research Article | published 24 Jul 2023 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1004274

Prevalence and predictors of COVID-19 vaccination hesitancy among healthcare workers in Sub-Saharan Africa: A systematic review and meta-analysis
Eustes Kigongo, Amir Kabunga, Raymond Tumwesigye, Marvin Musinguzi, Ronald Izaruku, Walter Acup
Research Article | published 28 Jul 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0289295

Caregivers’ perception and acceptance of malaria vaccine for Children
Victoria Bam, Abdulai Mohammed, Abigail Kusi-Amponsah, Jerry Armah, Alberta Yemotsoo Lomotey, Hayford Isaac Budu, Collins Atta Poku, Joana Kyeli-Dompim, Catherine Dwumfour
Research Article | published 26 Jul 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0288686

[No new digest content identified]
PNAS Nexus
Volume 2, Issue 6  June 2023
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]

Prehospital & Disaster Medicine
Volume 38 - Issue 3 - June 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 172  July 2023
[Reviewed earlier]

Proceedings of the Royal Society B
12 July 2023  Volume 290  Issue 2002
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 220  Pages 1-196 (July 2023)
[Reviewed earlier]

Public Health Ethics
Volume 16, Issue 1, April 2023
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 4, July/August 2023
https://journals.sagepub.com/toc/phrg/138/4
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 8-9, July 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]
Research Ethics
Volume 19 Issue 3, July 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 29 Jul 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
24 Jul 2023
READ-ing antimicrobial stewardship in the Caribbean: a tri-nation document review
Original research | English |

24 Jul 2023
Elimination of cervical cancer in Latin America (Project ECHO-ELA): lessons from phase one of implementation
Original research | English |

24 Jul 2023
COVID-19 mortality in metropolitan areas and other regions of Brazil, 2020 to 2021
Original research | Portuguese |

Risk Analysis
Volume 43, Issue 7  Pages: 1297-1519  July 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 29 Jul 2023]
[No new digest content identified]

Science
Volume 381| Issue 6656| 28 Jul 2023
https://www.science.org/toc/science/current
[New issue; No digest content identified]
Mitigating the impacts of the COVID-19 pandemic on vulnerable populations: Lessons for improving health and social equity
Si Ying Tan, Chuan De Foo, Monica Verma, Piya Hanvoravongchai, ... Helena Legido-Quigley
Article 116007

The impact of the COVID-19 pandemic on inequalities in preventive health screenings: Trends and implications for U.S. population health
Sneha Sarah Mani, Rebecca Anna Schut
Article 116003
Assessing the Influence of COVID-19 Vaccination Coverage on Excess Mortality across 178 Countries: A Cross-Sectional Study
by Oliver Mendoza-Cano

Abstract
The COVID-19 pandemic has had a devastating impact on global health, necessitating urgent and effective strategies to mitigate its consequences. Vaccination programs have been implemented worldwide to combat virus transmission and reduce the disease burden. This study aimed to investigate the relationship between COVID-19 vaccination coverage and all-cause excess mortality in 178 nations during the first two years of the pandemic. Multiple regression analysis, after adjusting for life expectancy at birth, confirmed a significant association between higher vaccination coverage and lower all-cause mortality rates ($\beta = -106.8, 95\% \text{ CI} -175.4 \text{ to } -38.2, p = 0.002$). These findings underscore the importance of vaccination campaigns in reducing overall mortality during the COVID-19 pandemic. Evidence-based decision making and resource allocation can benefit from this information, facilitating the optimization of vaccination strategies for maximal impact on mortality reduction. Further research and continuous monitoring are crucial to understanding the long-term effects of vaccination coverage on population health in the ongoing pandemic.
Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013
Marthe Knijff, Alies van Lier, Maartje Boer, Marion de Vries, Jeanne-Marie Hament, Hester E. de Melker

Attitudes and Perceptions of Medical Researchers Towards the Use of Artificial Intelligence Chatbots in the Scientific Process: A Protocol for a Cross-Sectional Survey
Jeremy Y. Ng, Sharleen G. Maduranayagam, Cynthia Lokker, Alfonso Iorio, R. Brian Haynes, David Moher

The historical fingerprint and future impact of climate change on childhood malaria in Africa
Colin J. Carlson, Tamma A. Carleton, Romaric C. Odoulami, Christopher H. Trisos
medRxiv 2023.07.16.23292713; doi: https://doi.org/10.1101/2023.07.16.23292713 Revision

Factors influencing COVID-19 vaccination decision-making among African American and Hispanic pregnant and postpartum women in Deep South
Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: a prospective population-based study in rural Bangladesh
medRxiv 2023.07.23.23292706; doi: https://doi.org/10.1101/2023.07.23.23292706

The Political Division toward COVID-19, Vaccines, Contact Tracing Apps, and A Future Pandemic Scenario in the United States: A Survey Result from A National Representative Sample
Haijing Hao, Garrett Smith, Yunan Chen, Mainack Mondal, Po-Shen Loh, Staci Smith, Xinru Page
medRxiv 2023.07.20.23292950; doi: https://doi.org/10.1101/2023.07.20.23292950

Artificial Intelligence in Biomedicine: Systematic Review
Irene S. Gabashvili
medRxiv 2023.07.23.23292672; doi: https://doi.org/10.1101/2023.07.23.23292672

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 29 Jul 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.
[We are temporarily suspending active coverage of this resource due to “posting pollution”]

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 29 Jul 2023]
Selected Research
Research Article  Open Access
REVISED- Medical debt during epidemics: A case for resolving the situation in low- and middle-income countries such as Kenya [version 2; peer review: 4 approved with reservations]
Tom Obengo

Software Tool Article  Open Access
Predictive Clinical Neuroscience Portal (PCNportal): instant online access to research-grade normative models for clinical neuroscientists. [version 1; peer review: awaiting peer review]
Abstract
Background: The neurobiology of mental disorders remains poorly understood despite substantial scientific efforts, due to large clinical heterogeneity and to a lack of tools suitable to map individual variability. Normative modeling is one recently successful framework that can address these problems by comparing individuals to a reference population. The methodological underpinnings of normative modelling are, however, relatively complex and computationally expensive. Our research group has developed the python-based normative modelling package Predictive Clinical Neuroscience toolkit (PCNtoolkit) which provides access to many validated algorithms for normative modelling. PCNtoolkit has since proven to be a strong foundation for large scale normative modelling, but still requires significant computation power, time and technical expertise to develop.

Methods: To address these problems, we introduce PCNportal. PCNportal is an online platform integrated with PCNtoolkit that offers access to pre-trained research-grade normative models estimated on tens of thousands of participants, without the need for computation power or programming abilities. PCNportal is an easy-to-use web interface that is highly scalable to large user bases as necessary. Finally, we demonstrate how the resulting normalized deviation scores can be used in a clinical application through a schizophrenia classification task applied to cortical thickness and volumetric data from the longitudinal Northwestern University Schizophrenia Data and Software Tool (NUSDAST) dataset.

Results: At each longitudinal timepoint, the transferred normative models achieved a mean[std. dev.] explained variance of 9.4[8.8]%, 9.2[9.2]%, 5.6[7.4]% respectively in the control group and 4.7[5.5]%, 6.0[6.2]%, 4.2[6.9]% in the schizophrenia group. Diagnostic classifiers achieved AUC of 0.78, 0.76 and 0.71 respectively.

Conclusions: This replicates the utility of normative models for diagnostic classification of schizophrenia and showcases the use of PCNportal for clinical neuroimaging. By facilitating and speeding up research with high-quality normative models, this work contributes to research in inter-individual variability, clinical heterogeneity and precision medicine.

Systematic Review  Open Access
UPDATE A living mapping review for COVID-19 funded research projects: final (27 month) update [version 10; peer review: 2 approved]
Previously titled: A living mapping review for COVID-19 funded research projects: two year update
Adrian Bucher, et al.
Abstract
Background: The coronavirus disease 2019 (COVID-19) has resulted in an unprecedented research response, demonstrating exceptional examples of rapid research and collaboration. There has however been an ongoing need for greater coordination, with limited resources for research and the shifting global pandemic.

Methods: The UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), two funder coordination groups have collaborated to develop a live database of funded research projects across the world relating to COVID-19. Drawing data continually from their members and further global funding bodies, as of 15th October 2022 the database contains 20,006 projects, funded by 351 funders, taking place across 157 countries representing an investment of at least $7.4 billion. To our knowledge it is one of the most comprehensive databases. The database is aligned to the World Health Organisation and GloPID-R Global Research Roadmap: 2019 Novel Coronavirus and the UN Research Roadmap for the COVID-19 Recovery. It is being used by the WHO, governments and further policy makers, research funders and researchers.

This living mapping review aims to supplement the database by providing an open, accessible, and
frequently updated resource summarising the characteristics of the COVID-19 funded research portfolio. Both descriptive and thematic analyses are presented and updated frequently to aid interpretation of the global COVID-19 funded research portfolio.

Results: In this final version ten analysis, we provide an updated detailed descriptive analysis of the database (on data from three months after version nine) and focus our thematic analysis on research gaps, research areas in need of coordination, study populations, and research locations (with a focus on resource-limited countries).

Conclusions: As the global research response to COVID-19 plateaus, this living mapping review has helped both funders and researchers to prioritise resources and review investments.

* * * *

**Think Tanks**

**Brookings** [to 29 Jul 2023]
http://www.brookings.edu/

*Latest Research [Selected]*
*No new digest content identified.*

**Center for Global Development** [to 29 Jul 2023]
https://www.cgdev.org/

*All Research [Selected]*
*No new digest content identified.*

**Chatham House** [to 29 Jul 2023]
https://www.chathamhouse.org/

*Selected Analysis, Comment, Events*

**Research paper**
**China's new scientists**
Achieving Xi Jinping’s ambitious agenda of self-reliance in critical technologies will become all the more difficult as the space for creative thinking within China narrows, and opportunities diminish for Chinese scientists to work with peers internationally.
24 July 2023

**Council on Foreign Relations** [to 29 Jul 2023]
https://www.cfr.org/media/news-releases

*New Releases [Selected]*
*No new digest content identified.*

**CSIS** [to 29 Jul 2023]
https://www.csis.org/

*Selected Reports, Events*
*No new digest content identified.*
Kaiser Family Foundation  [to29 Jul 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute  [to 29 Jul 2023]
https://www.mckinsey.com/mgi/overview
Latest Research
Generative AI and the future of work in America
July 26, 2023 – Multiple forces are set to fuel growth in certain occupations and erode jobs in others.

ODI [Overseas Development Institute]  [to 29 Jul 2023]
Publications [Selected]
No new digest content identified.

Pew Research Center  [to 29 Jul 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

Rand  [to 29 Jul 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
No new digest content identified.

Urban Institute  [to 29 Jul 2023]
https://www.urban.org/publications
New Research Publications - Selected

Research Report
Advancing Vaccine Equity through Community-Based Organizations
July 26, 2023
The Centers for Disease Control and Prevention (CDC) launched the Partnering for Vaccine Equity (P4VE) program in 2020 to address racial and ethnic disparities in adult immunization rates, particularly for COVID-19 and influenza. In 2021, P4VE directed $156 million to over 500 national, state, and community-based organizations (CBOs) to improve equitable access to vaccination in communities by promoting vaccine confidence and addressing barriers to vaccination opportunities.

The Urban Institute is partnering with CDC to support a subset of CBOs participating in the P4VE program. In the first year of the P4VE initiative (April 30, 2021, to April 29, 2022), the Urban Institute provided grant subawards and tailored program support and technical assistance to 29 CBOs. This
report presents findings from an evaluation of CBOs’ performance on P4VE program objectives in the first year, including challenges and successes CBOs experienced in their efforts to improve vaccine equity.

**World Economic Forum**  [to 29 Jul 2023]
https://agenda.weforum.org/news/

*Media*

**Macroeconomic and Geopolitical Conditions Pose Severe Risks to Organizations, say Chief Risk Officers**
News 26 Jul 2023
- Geopolitical and geoeconomic relations between major economies are set to experience significant volatility over the next six months, according to the World Economic Forum’s Chief Risk Officers community
- New survey suggests 85% of CROs expect continued shocks in economic and financial conditions
- Armed conflicts and regulatory changes are also cited as potential threats to organizations
- Over 75% of CROs believe the use of AI technologies poses reputational risks to their organisation
- For more information, read the white paper [here](https://agenda.weforum.org/news/)

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::::

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.
Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*   *   *   *
*   *   *   *
*   *   *   *